Tapentadol HCl API Powder by Cerata Pharmaceuticals LLP

Tapentadol HCl API powder is manufactured and exported globally by Cerata Pharmaceuticals LLP which is a leading API maker for pain management medicines. Tapentadol HCl functions as an opioid analgesic of the mu-opioid receptor agonist as well as an inhibitor of norepinephrine reuptake in the central nervous system, for the management of moderate to severe pain.

Product Details:

Product: Tapentadol HCl API Powder

Manufacturer/Exporter: Cerata Pharmaceuticals LLP

Grades Available:

USP (United States Pharmacopeia).

IP (Indian Pharmacopeia)

BP (British Pharmacopeia)

Use of Tapentadol HCL

Pain Management: Tapentadol HCl is mainly indicated for:

Management of moderate to severe acute pain due tourgery or injuries.

For example, chronic pain that includes lower back pain or osteoporosis.

Peripheral neuropathy is also defined as diabetic neuropathy; neuropathic pain or nerve pain.

Patients’ pain control after surgery

Mechanism of Action: Tapentadol for its analgesic effect acts anatomistically as a mu-opioid agonist and works synergistically with serotonin inhibitors and noradrenaline re-uptake inhibitors.

1. Mu-opioid receptor agonist: Influences the CNS by meant to decreasing the sensation of pain.

2. Norepinephrine reuptake inhibitor (NRI): Prevents reuptake of norepinephrine in the CNS; elevates levels which are associated with pain reduction.

Specifications of Tapentadol HCl API:

Appearance: White to off-white crystalline powder.

Purity: As a rule, it should be Non-First order, > 99% (depending on market and pharmacopoeial requirements).

Solubility: Hydrophilic, and soluble in water and ethanol.

Melting Point: 198–204°C

pH: 4.0–6.0 (in aqueous solution)

Specific Rotation: Between +95° and +105°

Market Demand & Applications:

Market Requirements: In light of the growing demand for commodities in managing severe pains Manuscripts, the substance tapentadol HCl is prescribed in many countries for the treatment of chronic severe pain. It is in this regard that Cerata Pharmaceuticals provides USP/IP/BP compliant Tapentadol HCl to meet this need of the highest purity.

Countries Exported to: Cerata Pharmaceuticals has a wide range of distribution markets of Tapentadol HCl to North America, Europe, Asia, and Latin America where opioid based analgesia is required for both female and male acute and chronic pain.

Formulations:

Oral Tablets/Extended-release tablets: Tapentadol HCl is typically administered as an immediate or extended-release oral tablet to effect long term pain relief.

Injectables: Utilized in certain facilities where it may be used in postoperative analgesia or for exacerbating acute pain.

Compliance with International Standards:

Tapentadol HCl is synthesized at Cerata Pharmaceuticals at USP IP and BP standards to facilitate approval across various international regions. This product has gone through various quality tests to ensure that satisfies the pharmacopoeial-quality to be used in the pharmaceutical formulation.

If you wish to know more about regulatory guidelines or other relevant market issues for Tapentadol HCl please let me know your details related requirements.